FDA of­fers new draft guid­ance on can­cer drug dose op­ti­miza­tion with over­haul of max­i­mum tol­er­at­ed dose par­a­digm

Al­though spon­sors of can­cer drugs have his­tor­i­cal­ly gone af­ter the max­i­mum tol­er­at­ed dose (MTD), par­tic­u­lar­ly with chemother­a­py, the FDA re­leased new draft guid­ance to­day ex­plain­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER